A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
12/2002
12/19/2002	CA2449934A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449654A1 Methods for treating disorders of the nervous and reproductive systems
12/19/2002	CA2449649A1 A g-protein coupled receptor and uses therefor
12/19/2002	CA2449629A1 Pyrrolidine derivatives as factor xa inhibitors
12/19/2002	CA2449517A1 Tissue-specific endothelial membrane proteins
12/19/2002	CA2449256A1 Modulators of peroxisome proliferator activated receptors
12/19/2002	CA2449189A1 Naphtothiazine positive allosteric ampa receptor modulators (paarm)
12/19/2002	CA2448552A1 Modulators of peroxisome proliferator activated receptors (ppar)
12/19/2002	CA2447687A1 Substituted 1-benzazepines and derivatives thereof
12/19/2002	CA2447557A1 Using supercritical fluids to infuse therapeutic on a medical device
12/19/2002	CA2446223A1 Stabilized dispersion of phytosterol in oil
12/18/2002	EP1267171A1 Cofactor-based screening method for nuclear receptor modulators
12/18/2002	EP1266899A2 Rapamycin hdroxyesters, process for their preparation and pharmaceutical compositions containing them
12/18/2002	EP1266896A1 Linear ou cyclic ureas, process for their preparation and pharmaceutical compositions containing them
12/18/2002	EP1266888A1 Quinoline derivatives and medicinal use thereof
12/18/2002	EP1266660A1 Heme oxygenase-1 inducers or induction enhancers
12/18/2002	EP1266654A1 Stabilised amlodipine maleate formulations
12/18/2002	EP1266227A1 Synergistic activation of regulatory elements by rel proteins and a steroid receptor
12/18/2002	EP1266013A2 Heparinase iii and uses thereof
12/18/2002	EP1266012A2 Proteases
12/18/2002	EP1266008A2 Acute neuronal induced calcium binding protein type 1 ligand
12/18/2002	EP1266005A2 Regulation of human lipoxin a4 receptor-like protein
12/18/2002	EP1266002A2 Il-17 receptor like molecules and uses thereof
12/18/2002	EP1266001A2 Human transcription factors
12/18/2002	EP1266000A1 Chordin-like-2 molecules and uses thereof
12/18/2002	EP1265996A2 Identification of modulators of the interferon gamma signaling pathway and their use in restenosis treatment
12/18/2002	EP1265995A2 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
12/18/2002	EP1265920A2 Angiogenesis-associated proteins, and nucleic acids encoding the same
12/18/2002	EP1265919A2 G-protein associated molecules
12/18/2002	EP1265914A2 Wnt-1 related polypeptides, and nucleic acids encoding the same
12/18/2002	EP1265913A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
12/18/2002	EP1265905A1 Il-8 receptor antagonists
12/18/2002	EP1265904A1 Novel positive allosteric ampa receptor modulators (paarm), method for the production and use thereof as medicaments
12/18/2002	EP1265903A1 Thiepino[3,2-b]dihydropyridines and related compositions and methods
12/18/2002	EP1265900A1 1,5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
12/18/2002	EP1265899A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
12/18/2002	EP1265891A2 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
12/18/2002	EP1265881A1 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
12/18/2002	EP1265878A1 A process for the preparation of epothiline analogs and intermediates
12/18/2002	EP1265871A1 Pyridazinyl phenyl hydrazones useful against congestive heart failure
12/18/2002	EP1265870A1 New ccr5 modulators: benzimidazoles or benzotriazoles
12/18/2002	EP1265867A1 Novel malonic acid derivates, processes for their preparation, their use as inhibitor of factor xa activity and pharmaceutical compositions containing them
12/18/2002	EP1265866A2 Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof
12/18/2002	EP1265865A2 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
12/18/2002	EP1265863A1 Heterocyclic side chain containing metalloprotease inhibitors
12/18/2002	EP1265862A2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
12/18/2002	EP1265860A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
12/18/2002	EP1265859A2 Amidino compounds useful as nitric oxide synthase inhibitors
12/18/2002	EP1265853A1 Carboxylic acid derivatives as ip antagonists
12/18/2002	EP1265848A2 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
12/18/2002	EP1265839A1 Compounds active at the glucocorticoid receptor
12/18/2002	EP1265838A1 Novel fatty acid analogous
12/18/2002	EP1265683A1 Methods for extraction and reaction using supercritical fluids
12/18/2002	EP1265639A1 The use of anticoagulant agents in the extracorporeal treatment of blood
12/18/2002	EP1265636A2 Improved treatment of neovascularization
12/18/2002	EP1265621A2 Use of cdp-choline for the prophylactic treatment of cerebral ischemia
12/18/2002	EP1265616A2 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate
12/18/2002	EP1265614A1 Novel galenical form for oral administration with prolonged release of molsidomine
12/18/2002	EP1265603A2 Il-8 receptor antagonists
12/18/2002	EP1265602A2 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries
12/18/2002	EP1265596A2 Medical emulsion for lubrication and delivery of drugs
12/18/2002	EP1124814B1 Aromatic derivatives and iron complexes thereof for the use as normalising agents of the iron level
12/18/2002	EP1086101B1 Beta-carboline compounds
12/18/2002	EP1068240B1 Method for sterilising native collagen in liquid medium, resulting native collagen, compositions containing same and uses
12/18/2002	EP0946502B1 Sulfonamide interleukin-beta converting enzyme inhibitors
12/18/2002	EP0934300B1 The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
12/18/2002	EP0892811B1 Peptides with antiproliferative properties
12/18/2002	EP0891344B1 Alpha-1 adrenergic receptor antagonists
12/18/2002	EP0880526B1 Heterocycle-condensed morphinoid derivatives (ii)
12/18/2002	EP0873309B1 3-spiro-indolin-2-one derivatives as vasopressin and/or oxytocin receptor ligands
12/18/2002	EP0859784B1 Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation
12/18/2002	EP0859607B1 Guanidino protease inhibitors
12/18/2002	EP0832085B1 Phosphinic acid derivatives with metallopeptidase inhibitory activity
12/18/2002	CN1385532A Expression system utilizing self-schizolysis fusing protein and novel reduction polypeptide
12/18/2002	CN1385529A Expression system utilizing self-schizolysis fusing protein and novel reduction polypeptide
12/18/2002	CN1385210A Process for preparing Chinese medicine stasis-removing and fat-reducing pill
12/18/2002	CN1385206A Zhongfengnaoxintong for treating apoplexy
12/18/2002	CN1385196A Multi-function health care food and application thereof
12/18/2002	CN1385189A Oral medicine for treating pile
12/18/2002	CN1385188A Method for extracting and separating effective part from dogbane
12/18/2002	CN1385185A Method for producing Naoxin'an Chinese medicinal capsule used for trating hemiparalysis, obstruction of qi in the chest and cardialgia
12/18/2002	CN1385184A Method for producing Huonaoxin Chinese medicinal capsule used for traeting cardi-cerebral vascular disease
12/18/2002	CN1385163A Process for preparing novel medicine for breviscapine having function of promoting blood circulation and removing blood stasis
12/18/2002	CN1385162A Erigreron breviscapus extract controlled releasing tablet and preparation method thereof
12/18/2002	CN1385155A Punerarin oral capsule and oral liquid
12/18/2002	CN1385151A Slow-released dosage form of sodium ferulate and preparation process thereof
12/18/2002	CN1096465C Isosorbierite-ester nitrate devirant and application used as survirability reduced vasodilator agent
12/18/2002	CN1096464C 2,3-benzodiazepine derivatives, its preparation and intermediate and use as medicine
12/18/2002	CN1096277C Perfume liquid extract capable of improving indoor air and regulating qi and blood
12/18/2002	CN1096269C Medicinal composition for treating cardiovascular disease and its preparing process
12/18/2002	CN1096265C Preparation of pharmaceutical composition containing novel thiazolidone and oxazolidone
12/18/2002	CA2388761A1 Wound healing biomarkers
12/17/2002	US6495687 Adenosine receptors are involved in a vast number of peripheral and central regulatory mechanisms such as, for example, vasodilation, cardiac depression, inhibition of lipolysis, inhibition of insulin release and potentiation
12/17/2002	US6495684 Inhibit human factor xa; treating diseases characterized by thrombotic activity; for example 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2,3 -dihydroxypropoxy)pyridin-2-yl)oxy)-4-hydroxybenzamidine
12/17/2002	US6495608 Methods of performing surgery with galactomannan polymers and borate
12/17/2002	US6495606 Administering s-((r)-2-(1-iminoethylamino)propyl)-l-cysteine
12/17/2002	US6495604 Cycloalkene derivatives, process for producing the same, and use
12/17/2002	US6495593 Purified proanthocyanidin as antiischemics of reperfusion injureis, and an artificial blood substitute inducing the ischemic reperfusion injury upon introduction into the body of a person
12/17/2002	US6495587 Tricyclic indole-2-carboxylic acid compound used as NMDA receptor antagonist
12/17/2002	US6495582 Erk (extracellular signal regulated kinase) inhibitors for treatment of cancer, inflammatory disorders, restenosis, and cardiovascular disease

1 ... 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 ... 1595